Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

The T2D cohort was similarly split into cohorts 1b for T2D + tirzepatide (n = 4223) and 2b for T2D + semaglutide (n = 4223). In both the groups, the mean age of participants was 53.9-54 years; 60% ...

Assessing the real-world effect of semaglutide and tirzepatide on weight loss provides a glimpse into what we may see with the recently approved obesity drug tirzepatide and how it might compare ...

Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta ...

They were new initiators on tirzepatide or semaglutide labeled for type 2 diabetes from May 1, 2022 (the month of tirzepatide approval), through September 30, 2023.

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

In a head-to-head comparison, ... More than 42% of people taking tirzepatide had 15% or greater weight loss than the approximately 18% taking semaglutide. Tirzepatide is produced by Eli Lilly and ...

If approved for weight management, tirzepatide could top $50 billion in annual sales, five times the amount of semaglutide medications like Ozempic and Wegovy, which produced nearly $10 billion in ...